Advertisement

Molecular Diagnosis & Therapy

, Volume 14, Issue 2, pp 131–136 | Cite as

Molecular Medicine Tri-Conference 2010

Shaping Future Medicine
  • Anne Bardsley-Elliot
Meeting Report
  • 15 Downloads

Cambridge Healthtech Institute’s 17th International Molecular Medicine Tri-Conference convened February 3–5, 2010, at San Francisco’s Moscone North Convention Center, welcoming over 2700 attendees from 38 countries. Along with regular delegates, the 1223 participating companies, 130 exhibitors, and 44 sponsors engaged in the recurring Tri-Conference theme of ‘Shaping Future Medicine.’

Medicine: Personalized

The conference again had a strong focus on personalized medicine, in all its multiple forms. Keynote speaker John Crowley, CEO of Amicus Therapeutics, Inc., captivated the audience with his truly personal story of social entrepreneur-ship in drug research, inspired by the 1998 diagnosis of glycogen storage disease type II (Pompe disease) — a rare and often fatal genetic neuromuscular disorder — in two of his infant children. Historically, drug companies have lacked the financial incentive to develop treatments for such orphan diseases. So Crowley, driven by motivation to help his...

Keywords

Breast Cancer Trastuzumab Personalized Medicine Glycogen Storage Disease Translational Medicine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Small GW, Moody TD, Siddarth P, et al. Your brain on Google: patterns of cerebral activation during internet searching. Am J Geriatr Psychiatry 2009 Feb; 17(2): 116–26PubMedCrossRefGoogle Scholar
  2. 2.
    Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20(8): 1319–29PubMedCrossRefGoogle Scholar
  3. 3.
    Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982; 5(3): 361–6CrossRefGoogle Scholar
  4. 4.
    US FDA. Mammaprint 510k summary [online]. Available from URL: http://www.accessdata.fda.gov/cdrh_docs/pdf8/K081092.pdf [Accessed 2010 Mar 17]
  5. 5.
    European Organization for Research and Treatment of Cancer. Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes (MINDACT) [Clinical-Trials.gov identifier NCT00433589]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00433589?term=mindact&rank=1 [Accessed 2010 Mar 17]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Anne Bardsley-Elliot
    • 1
  1. 1.Adis JournalsAucklandNew Zealand

Personalised recommendations